Testosterone replacement therapy in relation with cardiovascular disease in cisgender women and transgender people.
David S LopezJuwairia S MullaDanielle El HaddadMd Ibrahim TahashilderEfstathia PolychronopolouJacques BaillargeonAshwani K SingalSyed GilaniWissam I KhalifePublished in: The Journal of clinical endocrinology and metabolism (2023)
Use of TTh increased the risk of CVD, CAD and stroke among is cisgender women, but not among transgender people. TTh is becoming more widely accepted in women, and it is the main medical treatment for transgender males. Therefore, use of TTh should be further investigated for the prevention of CVD.
Keyphrases
- replacement therapy
- polycystic ovary syndrome
- cardiovascular disease
- pregnancy outcomes
- smoking cessation
- hiv testing
- cervical cancer screening
- healthcare
- breast cancer risk
- atrial fibrillation
- type diabetes
- insulin resistance
- men who have sex with men
- adipose tissue
- metabolic syndrome
- blood brain barrier
- cardiovascular risk factors